[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcCbeFw-r6oPtkYJt5liCT5N4XIN811rFrvSqRHc6hj8":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":12,"question":19,"related":20,"source":31,"type":32},[],"2025-12-14 06:53:03",263645621,[8,9,10,11],"美托洛尔","阿替洛尔","拉贝洛尔","普萘洛尔",{"count":13,"courseId":14,"courseImg":15,"courseName":16,"workId":17,"workName":18},6,"53e1d2ef4961cca8eea3e23969ad2cb9","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002F03a579384a6dc297c89809b582fcc767.png","默认课程","work_47006830","预习16","无内在拟交感活性的非选择性β受体阻断药是( )",[21,33,42,51,56,59],{"answer":22,"createTime":23,"id":24,"options":25,"question":30,"source":31,"type":32},[],"2025-10-19 18:10:58",222573459,[26,27,28,29],"1400","2000","3000","2100","A、B两家公司同属甲公司的子公司.A公司于2015年3月1日以发行股票方式从B公司的股东手中取得B公司70%的股份.A公司发行2 000万股普通股股票,该股票每股面值为1元.B公司在2015年3月1日所有者权益账面价值为3 000万,A公司该项长期股权投资的成本为( )万元","v1",0,{"answer":34,"createTime":5,"id":35,"options":36,"question":41,"source":31,"type":32},[],263645615,[37,38,39,40],"N1受体阻断药","α受体阻断药","N2受体阻断药","M受体阻断药","可翻转肾上腺素升压效应的药物是( )",{"answer":43,"createTime":5,"id":44,"options":45,"question":50,"source":31,"type":32},[],263645617,[46,47,48,49],"新斯的明","酚妥拉明","酚苄明","甲氧明","下列属非竞争性α受体阻断药是( )",{"answer":52,"createTime":5,"id":53,"options":54,"question":55,"source":31,"type":32},[],263645619,[46,47,48,49],"下列属竞争性α受体阻断药是( )",{"answer":57,"createTime":5,"id":6,"options":58,"question":19,"source":31,"type":32},[],[8,9,10,11],{"answer":60,"createTime":5,"id":61,"options":62,"question":63,"source":31,"type":32},[],263645622,[10,48,11,8],"治疗外周血管痉挛性疾病的药物是( )"]